Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TOP1 | P11387 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22327509 | 1.00 | LMNA (0.46) | LMNAL3MBTL1TDP1TOP1KDM4E | |
| SCHEMBL2119845 | 0.94 | LMNA (0.41) | LMNAL3MBTL1TDP1TOP1KDM4E | |
| SCHEMBL22327580 | 0.94 | LMNA (0.48) | LMNAL3MBTL1TDP1TOP1KDM4E | |
| SCHEMBL13169240 | 0.93 | GGPS1 (0.49) | LMNAL3MBTL1TDP1TOP1KDM4E | |
| SCHEMBL4754900 | 0.93 | GGPS1 (0.49) | LMNAL3MBTL1TDP1TOP1KDM4E | |
| SCHEMBL23016843 | 0.93 | GGPS1 (0.49) | LMNAL3MBTL1TDP1TOP1KDM4E | |
| SCHEMBL8640646 | 0.93 | GGPS1 (0.49) | LMNAL3MBTL1TDP1TOP1KDM4E | |
| SCHEMBL12258773 | 0.93 | GGPS1 (0.49) | LMNAL3MBTL1TDP1TOP1KDM4E | |
| SCHEMBL13169239 | 0.93 | GGPS1 (0.49) | LMNAL3MBTL1TDP1TOP1KDM4E | |
| SCHEMBL789161 | 0.93 | GGPS1 (0.49) | LMNAL3MBTL1TDP1TOP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234228-A1 | NOVEL SURFACTANTS AND FORMULATIONS | MONSANTO TECHNOLOGY LLC (US) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234228-A1 | NOVEL SURFACTANTS AND FORMULATIONS | PHOSPHO1, GNMT, DDT | LMNA 2033/4885L3MBTL1 2899/4885TDP1 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.